全文获取类型
收费全文 | 31376篇 |
免费 | 2598篇 |
国内免费 | 1768篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 525篇 |
妇产科学 | 149篇 |
基础医学 | 4536篇 |
口腔科学 | 94篇 |
临床医学 | 2743篇 |
内科学 | 13089篇 |
皮肤病学 | 149篇 |
神经病学 | 250篇 |
特种医学 | 544篇 |
外国民族医学 | 4篇 |
外科学 | 1027篇 |
综合类 | 5829篇 |
现状与发展 | 11篇 |
预防医学 | 2540篇 |
眼科学 | 30篇 |
药学 | 2324篇 |
11篇 | |
中国医学 | 1324篇 |
肿瘤学 | 534篇 |
出版年
2024年 | 34篇 |
2023年 | 396篇 |
2022年 | 697篇 |
2021年 | 887篇 |
2020年 | 924篇 |
2019年 | 1019篇 |
2018年 | 926篇 |
2017年 | 1024篇 |
2016年 | 1240篇 |
2015年 | 1273篇 |
2014年 | 1970篇 |
2013年 | 2097篇 |
2012年 | 1876篇 |
2011年 | 2250篇 |
2010年 | 1704篇 |
2009年 | 1552篇 |
2008年 | 1568篇 |
2007年 | 1679篇 |
2006年 | 1625篇 |
2005年 | 1326篇 |
2004年 | 1141篇 |
2003年 | 1042篇 |
2002年 | 909篇 |
2001年 | 933篇 |
2000年 | 765篇 |
1999年 | 615篇 |
1998年 | 518篇 |
1997年 | 495篇 |
1996年 | 438篇 |
1995年 | 444篇 |
1994年 | 380篇 |
1993年 | 314篇 |
1992年 | 275篇 |
1991年 | 211篇 |
1990年 | 169篇 |
1989年 | 140篇 |
1988年 | 145篇 |
1987年 | 116篇 |
1986年 | 93篇 |
1985年 | 102篇 |
1984年 | 85篇 |
1983年 | 51篇 |
1982年 | 60篇 |
1981年 | 50篇 |
1980年 | 54篇 |
1979年 | 33篇 |
1978年 | 38篇 |
1977年 | 23篇 |
1976年 | 9篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
《Revista de gastroenterologia de Mexico》2021,86(4):403-432
Hepatitis B virus (HBV) infection continues to be a worldwide public health problem. In Mexico, at least three million adults are estimated to have acquired hepatitis B (total hepatitis B core antibody [anti-HBc]-positive), and of those, 300,000 active carriers (hepatitis B surface antigen [HBsAg]-positive) could require treatment. Because HBV is preventable through vaccination, its universal application should be emphasized. HBV infection is a major risk factor for developing hepatocellular carcinoma. Semi-annual liver ultrasound and serum alpha-fetoprotein testing favor early detection of that cancer and should be carried out in all patients with chronic HBV infection, regardless of the presence of advanced fibrosis or cirrhosis. Currently, nucleoside/nucleotide analogues that have a high barrier to resistance are the first-line therapies. 相似文献
992.
目的:观察熊去氧胆酸治疗婴儿肝炎综合征的临床疗效,并初步探讨其药理机制。方法:选择76例婴儿肝炎综合征患儿为研究对象,根据治疗方法不同分为常规治疗组及熊去氧胆酸治疗组,另选择同期门诊体检健康儿童20名作为对照组。常规治疗组给予抗病毒、护肝等治疗,熊去氧胆酸治疗组在常规治疗组基础上加用熊去氧胆酸(10 mg·kg-1·d-1),疗程为2~3周。治疗2周后,比较常规治疗组和熊去氧胆酸治疗组治疗前后血清总胆红素(TBIL)、直接胆红素(DBIL)、谷丙转氨酶(ALT)、谷氨酰转肽酶(GGT)、总胆汁酸(TBA)和TNF-α、IL-6的变化情况。结果:(1)婴儿肝炎综合征患儿血清TNF-α和IL-6均明显高于对照组(P0.01)。(2)常规治疗组患儿治疗后血清TBIL、DBIL、ALT、GGT、TBA及TNF-α和IL-6均较治疗前下降,差异有统计学意义(P0.01)。(3)熊去氧胆酸治疗组患儿治疗后血清TBIL、DBIL、ALT、GGT、TBA及TNF-α和IL-6均较常规治疗组显著降低,差异有统计学意义(P0.01)。结论:在常规治疗基础上加用熊去氧胆酸能更有效减轻婴儿肝炎综合征患儿全身炎症反应,减轻肝脏损伤。 相似文献
993.
目的 研究慢性丙型肝炎患者甲状腺功能与肝功能指标的关系.方法 收集196例慢性丙型肝炎患者,检测甲状腺功能及肝功能相关指标,并对甲状腺功能和肝功能的关系进行分析.结果 196例慢性丙型肝炎患者中38例存在甲状腺功能异常,其中2例为甲状腺功能亢进,3例为甲状腺功能减退,33例为亚临床甲状腺功能减退.血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、总蛋白(TP)、白蛋白(ALB)、球蛋白(GLO)水平在甲状腺功能正常组与甲状腺功能异常组中差异无统计学意义(P>0.05);肝功能相关指标不是甲状腺功能异常的危险因素(P>0.05).结论 19.4%慢性丙型肝炎患者存在甲状腺功能的异常,明显高于正常人群;肝功能水平对甲状腺功能异常无明显影响. 相似文献
994.
995.
《Clinical gastroenterology and hepatology》2022,20(3):674-681
- Download : Download high-res image (425KB)
- Download : Download full-size image
996.
997.
Koji Fukushima Yoshiyuki Ueno Hirokazu Kanegane Yoko Yamagiwa Jun Inoue Osamu Kido Futoshi Nagasaki Takayuki Kogure Eiji Kakazu Yu Nakagome Yasunori Matsuda Noriyuki Obara Osamu Kimura Tooru Shimosegawa 《Hepatology research》2008,38(4):415-420
Severe hepatitis with an indistinct etiology manifested in a 16-year-old boy who had no particular history. The histological features of the liver and clinical course of the patient were similar to those of patients with autoimmune hepatitis characterized by interface hepatitis and severe lobular inflammation of the liver and recurrent exacerbations of hepatitis. We administered intravenous glycyrrhizin preparation daily or three times a week combined with the oral administration of ursodeoxycholic acid daily throughout the term after the initial onset of disease for the control of disease activity. The normalization of the concentration of alanine aminotransferase in serum was achieved in response to the therapy during the course. The serum concentration of immunoglobulins of the patient gradually decreased from the onset of the disease to an unacceptable level without globulin preparation during the following period of 17 months. Immunological tests revealed impairment of immunoglobulin production bythe B cell population of the patient, which led to the diagnosis of the patient as common variable immunodeficiency (CVID). The patient, with improved liver histology after 27 months from the onset of disease, benefited from the current combination therapy without severe infection through the avoidance of overimmunosuppression. CVID is defined as a heterogeneous syndrome characterized by various degrees of hypogammaglobulinemia without any specific predisposing causes, frequently associated with autoimmunity. Diagnostic criteria and therapeutic options of persistent hepatitis with CVID are to be established, as discussed in the current report. 相似文献
998.
Martín-Carbonero L Puoti M García-Samaniego J De Luca A Losada E Quinzan G Bruno R Mariño A González M Núñez M Soriano V 《Journal of viral hepatitis》2008,15(10):710-715
SUMMARY: Hepatitis C virus (HCV) genotypes 1 and 4 respond less well to pegylated interferon (pegIFN) plus ribavirin (RBV) therapy. For this reason most studies merge these two genotypes when assessing virological response. However, in most trials the HCV genotype 4 population is rather small, and conclusions are mainly derived from what occurs in HCV-1 patients. All HCV-4 patients coinfected with HIV who received pegIFN plus RBV in two different multicentre studies, PRESCO and ROMANCE, conducted respectively in Spain and Italy, were retrospectively analyzed. Baseline plasma HCV-RNA, proportion of patients with HCV-RNA <10 IU / mL at week 4 (rapid virological response), and HCV-RNA declines >2 logs at week 12 (early virological response, EVR) were all assessed as predictors of sustained virological response (SVR). Overall, 75 patients (60 men) were evaluated. Median age was 40 years and median CD4 count 598 cells / mm(3); 49% had plasma HIV-RNA <50 copies / mL; 71% had elevated liver enzymes and 31% had advanced liver fibrosis (Metavir F3-F4). Median serum HCV-RNA was 5.7 log IU / mL. Rapid virological response was attained by 10 (20%) patients and EVR by 26 (42%). Using intention-to-treat and on-treatment (OT) analyses, SVR was achieved by 21 / 75 (28%) and 21 / 62 (34%) of HCV-4 patients, respectively. In the multivariate analysis (OT), baseline HCV-RNA (OR 0.09 for every log increment; 95% CI: 0.01-0.7) and EVR (OR: 7.08; 95% CI: 1.8-27.2) were significantly and independently associated with SVR. This is the largest series of HIV-infected patients with chronic hepatitis C due to HCV-4 treated with pegIFN plus RBV examined so far and the results show that HCV-4 behaves similarly to HCV-1. Therefore, these patients should be considered as difficult to treat population. Baseline serum HCV-RNA and EVR are the best predictors of SVR in HCV-4 / HIV-coinfected patients. 相似文献
999.
Hsu TC Chen TY Lin MC Tzang BS Tsay GJ 《Journal of gastroenterology and hepatology》2005,20(5):733-738
BACKGROUND AND AIM: Parvovirus B19 has been reported to be detected in the sera of patients with acute or chronic hepatitis. The prevalence and clinical significance of B19 DNA in serum samples from patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection were investigated. METHODS: Serum samples from 54 patients with HBV infection, 51 with HCV infection and 53 normal controls were examined for anti-B19 antibodies and B19 DNA by enzyme-linked immunosorbent assay (ELISA), the nested polymerase chain reaction (PCR), Southern blotting and direct nucleotide sequencing, respectively. RESULTS: Anti-B19 IgM and IgG antibodies were detected in 19 (35.2%) and 46 (85.2%) of 54 serum samples from patients with HBV infection, and eight (15.7%) and 36 (70.6%) of 51 serum samples from patients with HCV infection. B19 DNA was detected in serum samples of 20 (37%) of 54 patients with HBV infection and 12 (23.5%) of 51 patients with HCV infection, but not in 53 serum samples from normal controls. The occurrence of liver dysfunction was not affected by B19 infection in patients with HBV and HCV infection (P > 0.05). All of the 20 serum samples with B19 DNA from patients with chronic HBV infection and all of the 12 serum samples with B19 DNA from patients with chronic HCV infection exhibited TW-3 subtype and TW-9 subtype, respectively. The variant subtypes of B19 were found to be distinctive in patients with HBV or HCV infection. CONCLUSIONS: These data revealed that human parvovirus B19 infection was frequently found in patients with chronic HBV or HCV infection. The variant genotypes were present in patients with different chronic hepatitis. The coinfection of B19 with HBV or HCV did not increase the frequency of liver dysfunction in patients with chronic hepatitis. Long-term longitudinal studies are required to determine the natural course of parvovirus B19 infection and whether its coinfection affects the natural history of chronic hepatitis B or hepatitis C. 相似文献
1000.
A significant number of patients with hepatitis C (HCV) treated with interferon (IFN) will initially clear their serum of HCV RNA, but will then have recurrence of viraemia either during or after therapy. One proposed mechanism for relapse is that HCV may persist in peripheral blood mononuclear cells (PBMCs) and that the PBMCs serve as a 'viral reservoir' that is resistant to IFN. To address this hypothesis, we performed serial, quantitative polymerase chain reaction (PCR) of HCV RNA in serum and PBMCs from 26 consecutive patients treated with IFN-α2a. Of the 26 patients, 11 (42%) did not clear virus from their serum during therapy and were termed non-responders. Five patients (19%) had sustained clearance of virus from serum and were termed complete responders. The remaining 10 patients (39%) initially eliminated HCV RNA from their serum, but had relapse of viraemia. They were termed partial responders. In all 10 partial responders HCV RNA was undetectable in PBMCs at the same time that it was undetectable in serum. When virus recurred in serum, it was preceded by or occurred at the same time as the return of virus in PBMCs. The results of our study indicate that PBMCs did not serve as an IFN-resistant 'viral reservoir' during therapy. Partial responders who transiently cleared virus from serum also cleared virus from PBMCs and the presence or titre of HCV RNA in PBMCs at the initiation of therapy did not predict response to therapy. 相似文献